Exhibit 6

Back to Results

A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

COMPLETED

To evaluate the effectiveness of patisiran in patients with ATTRv amyloidosis with polyneuropathy who have a V122I or T60A mutation.

Trial at a Glance

Trial ID	ALN-TTR02-012
Condition	Transthyretin Amyloidosis (ATTR)
Drug/Treatment	Patisiran
Does this trial use a placebo?	No
Trial Type	Observational
Number of Participants	67 participants
Trial dates	December 18, 2019 - May 24, 2022

For more information: NCT04201418

Who participated?

AGE

18+ Years

SEX

All

ACCEPTS HEALTHY VOLUNTEERS?

No

Where did the study take place?

Search location

Chapel Hill - Chapel Hill, NC, USA
Charlotte - Charlotte, NC, USA
Columbus - Columbus, OH, USA
Allentown - Allentown, PA, USA
Bethlehem - Bethlehem, PA, USA
Lancaster - Lancaster, PA, USA
Pittsburgh - Pittsburgh, PA, USA
Pittsburgh - Pittsburgh, PA, USA
Germantown - Germantown, TN, USA
Austin - Austin, TX, USA
San Antonio - 2455 NE Interstate 410 Loop #150, San Antonio, TX 78217, USA
Milwaukee - Milwaukee, WI, USA



Inquire about a clinical trial

Contact Alnylam directly with any questions about our clinical trials.

CONTACT US ›

Alnylam

Privacy policy Legal Notice Alnylam.com

Follow Us:

Completed

A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

ClinicalTrials.gov ID NCT04201418

Sponsor Alnylam Pharmaceuticals

Information provided by Alnylam Pharmaceuticals (Responsible Party)

Last Update Posted 2022-06-06

Study Details Tab

Study Overview

Brief Summary

To evaluate the effectiveness of patisiran in patients with ATTRv amyloidosis with polyneuropathy who have a V122I or T60A mutation.

Official Title

A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of Hereditary Transthyretin-Mediated (ATTRv) Amyloidosis With a V122I or T60A Mutation

Conditions

Hereditary Transthyretin-mediated (ATTRv) Amyloidosis | Polyneuropathy

Intervention / Treatment

- Drug: Patisiran

Other Study ID Numbers

- ALN-TTR02-012

Feedback

Study Start (Actual)

2019-12-18

Primary Completion (Actual)

2022-05-24

Study Completion (Actual)

2022-05-24

Enrollment (Actual)

67

Study Type

Observational

Resource links provided by the National Library of Medicine

MedlinePlus (https://medlineplus.gov/) related topics: Amyloidosis (https://medlineplus.gov/amyloidosis.html)

Genetic and Rare Diseases Information Center (https://rarediseases.info.nih.gov/gard) resources:
Familial Transthyretin Amyloidosis (https://rarediseases.info.nih.gov/diseases/656/familial-transthyretin-amyloidosis)
Amyloid Neuropathy (https://rarediseases.info.nih.gov/diseases/8708/amyloid-neuropathy)

Drug Information (https://dailymed.nlm.nih.gov/dailymed/) available for: Patisiran (https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=human&query=Patisiran)

FDA Drug and Device Resources (https://clinicaltrials.gov/fda-links)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Lancaster, Pennsylvania, United States, 17602
Clinical Trial Site

Pittsburgh, Pennsylvania, United States, 15212
Clinical Trial Site

Pittsburgh, Pennsylvania, United States, 15232
Clinical Trial Site

Tennessee Locations

Germantown, Tennessee, United States, 38138
Clinical Trial Site

Texas Locations



Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies (https://clinicaltrials.gov/study-basics/learn-about-studies).

Eligibility Criteria

Description

Inclusion Criteria:

- Diagnosed with ATTRv amyloidosis with polyneuropathy, with a documented V122I or T60A mutation
- PND score of I-IIIB at baseline.
- Exposure to commercial patisiran in one of the 3 cohorts:
  - Prospective Cohort: Naive to patisiran treatment at the time of enrollment with intention to initiate treatment with patisiran.
  - Mixed cohort: Currently on commercial patisiran therapy for less than 12 months at study enrollment.
  - Retrospective cohort: Exposed to commercial patisiran treatment for at least 12 months prior to study enrollment, regardless of current treatment status at enrollment.

Exclusion Criteria:

- New York Heart Association (NYHA) heart failure classification ≥3
- Karnofsky Performance Status (KPS) <60%
- Unstable congestive heart failure (CHF)
- Known primary amyloidosis (AL) or leptomeningeal amyloidosis
- Prior major organ transplant
- Previously received patisiran
- Previous treatment with a TTR silencing therapy

Study Population

Participants with ATTRv amyloidosis with polyneuropathy who have a V122I or T60A mutation

Ages Eligible for Study

18 Years and older (Adult, Older Adult)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Observational Model : Cohort
Time Perspective: Prospective

Groups and Interventions

Groups/Cohorts	Intervention/Treatment

Patisiran Prospective Cohort
 	
Patients who are naive to patisiran at study enrollment with the intention to initiate commercial patisiran therapy.
	Drug: Patisiran
	• Patisiran-lipid complex injection, for intravenous use
	• Other Names:
	  ◦ ONPATTRO
	  ◦ ALN-TTR02

Patisiran Mixed Cohort
 	
Patients who are currently on commercial patisiran therapy for less than 12 months at study enrollment.
	Drug: Patisiran
	• Patisiran-lipid complex injection, for intravenous use
	• Other Names:
	  ◦ ONPATTRO
	  ◦ ALN-TTR02

Patisiran Retrospective Cohort
 	
Patients who have been on commercial patisiran therapy for at least 12 months prior to study enrollment, regardless of current treatment status at enrollment.
	Drug: Patisiran
	• Patisiran-lipid complex injection, for intravenous use
	• Other Names:
	  ◦ ONPATTRO
	  ◦ ALN-TTR02

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants with Stable or Improved Polyneuropathy	PND Scores: Stage 0=No symptoms, Stage 1=Sensory disturbances but preserved walking capability, Stage 2=Impaired walking capacity, but ability to walk without a stick	Baseline, Month 12

Disability (PND) Score at 12 Months Relative to Baseline	or crutches, Stage 3A/B=Walking with the help of 1 or 2 sticks or crutches, Stage 4=confined to wheel chair or bedridden.	

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Alnylam Pharmaceuticals

Investigators

- Study Director: Medical Director, Alnylam Pharmaceuticals

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted
2019-12-13

First Submitted that Met QC Criteria
2019-12-13

First Posted
2019-12-17

Study Record Updates

Last Update Submitted that met QC Criteria
2022-06-03

Last Update Posted
2022-06-06

Last Verified
2022-06

More Information

Terms related to this study

Keywords Provided by Alnylam Pharmaceuticals

Valine to isoleucine substitution at position 122
V122I
Threonine to alanine substitution at position 60
T60A
Familial Amyloid Polyneuropathies
ATTR
Transthyretin amyloidosis
Transthyretin
Amyloidosis
TTR-mediated Amyloidosis
RNAi therapeutic
FAP
Polyneuropathies
Amyloid neuropathies
Amyloid neuropathies, familial
Amyloidosis, familial
Peripheral nervous system diseases
Nervous system diseases
TTR
Neuromuscular diseases
Proteostasis deficiencies
Metabolic diseases
Heredodegenerative disorders, nervous system
Neurodegenerative diseases
Genetic diseases, inborn
Metabolism, inborn errors
ATTRv

Additional Relevant MeSH Terms

Proteostasis Deficiencies
Metabolic Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Polyneuropathies
Amyloidosis

Plan for Individual Participant Data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents, and helpful links

Studies a U.S. FDA-Regulated Drug Product

Yes

Studies a U.S. FDA-Regulated Device Product

No

Product Manufactured in and Exported from the U.S.

No

Back to Results

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

ENROLLING

The purpose of this study is to: - Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients - Characterize the safety and effectiveness of patisiran as part of routine clinical practice in the real-world clinical setting - Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) mutation

Trial at a Glance

Trial ID	**ALN-TTR02-013**
Condition	**Transthyretin Amyloidosis (ATTR)**
Drug/Treatment	**Patisiran**
Does this trial use a placebo?	**No**
Trial Type	**Observational**
Number of Participants	**1500 participants**
Trial dates	**November 23, 2020 - September 1, 2030**

For more information: NCT04561518

Who can participate?

AGE
All

SEX
All

ACCEPTS HEALTHY VOLUNTEERS?
No

Where is the study taking place?

Search location

La Jolla - La Jolla, San Diego, CA, USA
Los Angeles - Los Angeles, CA, USA
Jacksonville - Jacksonville, FL, USA
Iowa City - Iowa City, IA, USA
Kansas City - Kansas City, KS, USA
Baltimore - Baltimore, MD, USA
Boston - Boston, MA, USA
New York - 59 E 54th St rm 93, New York, NY 10022, USA
Durham - Durham, NC, USA
Columbus - Columbus, OH, USA
Philadelphia - Philadelphia, PA, USA
Austin - Austin, TX, USA

Alnylam Clinical Trial Information Line

1-877-ALNYLAM
clinicaltrials@alnylam.com

Inquire about a clinical trial

Contact Alnylam directly with any questions about our clinical trials.

CONTACT US ›

Alnylam®

Privacy policy Legal Notice Alnylam.com

Follow Us:

Recruiting

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) (ConTTRibute)

ClinicalTrials.gov ID NCT04561518

Sponsor Alnylam Pharmaceuticals

Information provided by Alnylam Pharmaceuticals (Responsible Party)

Last Update Posted 2024-11-13

Study Details Tab

Study Overview

Brief Summary

The purpose of this study is to:

- Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients
- Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting
- Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant

Official Title

ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Conditions

Transthyretin-Mediated Amyloidosis | ATTR Amyloidosis

Other Study ID Numbers

- ALN-TTR02-013

Study Start (Actual)

2020-11-23

Primary Completion (Estimated)

2030-09-01

Study Completion (Estimated)

2030-09-01

Enrollment (Estimated)

1500

Study Type

Observational

Resource links provided by the National Library of Medicine

MedlinePlus (https://medlineplus.gov/) related topics: Amyloidosis (https://medlineplus.gov/amyloidosis.html)

Genetic and Rare Diseases Information Center (https://rarediseases.info.nih.gov/gard) resources: Familial Transthyretin Amyloidosis (https://rarediseases.info.nih.gov/diseases/656/familial-transthyretin-amyloidosis) Amyloid Neuropathy (https://rarediseases.info.nih.gov/diseases/8708/amyloid-neuropathy)

FDA Drug and Device Resources (https://clinicaltrials.gov/fda-links)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Alnylam Clinical Trial Information Line
Phone Number:
1-877-ALNYLAM
Email: clinicaltrials@alnylam.com

Study Contact Backup

Name: Alnylam Clinical Trial Information Line
Phone Number:
1-877-256-9526
Email: clinicaltrials@alnylam.com

Pennsylvania Locations

Philadelphia, Pennsylvania, United States, 19104
Recruiting
Clinical Trial Site

Texas Locations

Austin, Texas, United States, 78756
Recruiting
Clinical Trial Site

Houston, Texas, United States, 77030
Recruiting
Clinical Trial Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies (https://clinicaltrials.gov/study-basics/learn-about-studies).

Eligibility Criteria

Description

Inclusion Criteria:

- Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers
- Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis

Exclusion Criteria:

- Current enrollment in a clinical trial for any investigational agent

Study Population

Patients with a diagnosis of ATTR amyloidosis, hereditary or wild type, and pre-symptomatic carriers with a known disease-causing TTR variant will be eligible for the study.

Ages Eligible for Study

(Child, Adult, Older Adult)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Observational Model : Cohort
Time Perspective: Prospective

Groups and Interventions

Groups/Cohorts
Patients with ATTR amyloidosis Patients with a diagnosis of ATTR amyloidosis, hereditary or wild type, will be eligible for the study and will follow routine clinical care.
Pre-symptomatic Carriers Pre-symptomatic carriers with a known disease-causing TTR variant will be eligible for the study and will follow routine clinical care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Adverse Events		From time of enrollment for up to 10 years
Selected Events of Interest in Patients with Hereditary Transthyretin-mediated (hATTR) Amyloidosis (ATTRv Amyloidosis)	Selected events of interest are defined as hepatic events, cardiovascular events, renal events, ocular events and infusion-related reactions, hypersensitivity, and other events in patients diagnosed with hATTR amyloidosis.	From 1 year prior to enrollment for up to 10 years
Health Care Provider (HCP)-Assessed Polyneuropathy (PND) Disability Score	PND Scores: Stage 0=No symptoms; Stage I=Sensory disturbances but preserved walking capabilities; Stage II=Impaired walking capacity, but ability to walk without a stick or crutches; Stage IIIA=Walking with help of 1 stick or crutch; Stage IIIB=Walking with the help of 2 sticks or crutches; Stage IV=confined to wheel chair or bedridden.	Up to 11 years
HCP-Assessed Familial Amyloidotic Polyneuropathy (FAP) Score	FAP Scores: Stage 0=No symptoms; Stage I=Unimpaired ambulation; mostly mild sensory, motor and autonomic neuropathy in the lower limbs; Stage II=Assistance with ambulation required, mostly moderate impairment progression to the lower limbs, upper limbs, and trunk; Stage III=Wheelchair-bound or bedridden; severe sensory, motor, and autonomic involvement of all limbs.	Up to 11 years
HCP-Assessed Neuropathy Impairment Score (NIS)	NIS : 74 items, assess muscle weakness, reflexes and sensation; scored separately for left, right limbs (37 items for each side). Components of muscle weakness (hip and knee flexion, hip and knee	Up to 11 years

	extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) scored on scale 0 (normal) to 4 (paralysis), higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae) and sensation (touch pressure, pin-prick, vibration, joint position) scored 0 = normal, 1= decreased, or 2 = absent. Total possible NIS score range 0-244, higher score=greater impairment.	
HCP-Assessed Cardiomyopathy	Cardiomyopathy will be assessed using New York Heart Association (NYHA) Class: I=No symptoms; II=Symptoms with ordinary physical activity; III=Symptoms with less than ordinary physical activity; IV=Symptoms at rest.	Up to 11 years
HCP- Assessed Cardiopulmonary Exercise Testing (CPET) Performance		Up to 11 years
Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Score	Norfolk-QoL-DN: The Norfolk QOL-DN questionnaire is a standardized 35-item patient-reported outcomes measure that assesses 6 domains: physical function, large-fiber neuropathy, activities of daily living, symptoms, small-fiber neuropathy, and autonomic neuropathy. The total score ranges from -4 points (best possible quality of life) to 136 points (worst possible quality of life).	Up to 11 years
Kansas City Cardiomyopathy Questionnaire (KCCQ)	The KCCQ is a 23-item self-administered questionnaire developed to independently measure the patient's perception of health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life within a 2-week recall period. The KCCQ quantifies 6 domains (symptoms, physical function, quality of life, social limitation, self-efficacy, and symptom stability) and 2 summary scores (clinical and overall summary [OS] scores).	Up to 11 years
Rasch-built Overall Disability Scale (R-ODS)	The R-ODS is a 24-item self-administered questionnaire for assessment of the disability a patient experiences. It uses a linearly weighted categorical rating scale that specifically captures domains of activity and social participation limitations in patients.	Up to 11 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Alnylam Pharmaceuticals

Investigators

- Study Director: Medical Director, Alnylam Pharmaceuticals

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted
2020-09-18

First Submitted that Met QC Criteria
2020-09-18

First Posted
2020-09-23

Study Record Updates

Last Update Submitted that met QC Criteria
2024-11-12

Last Update Posted
2024-11-13

Last Verified
2024-11

More Information

Terms related to this study

Keywords Provided by Alnylam Pharmaceuticals

RNAi therapeutic
Transthyretin
TTR
Amyloidosis
Hereditary Transthyretin-mediated (hATTR) Amyloidosis
hATTR amyloidosis
Hereditary ATTR amyloidosis
Wild-type amyloidosis
wtATTR amyloidosis
ATTRv amyloidosis
ATTRwt amyloidosis
Polyneuropathy
Familial amyloid polyneuropathies
ATTR
Transthyretin amyloidosis
TTR-mediated amyloidosis
Polyneuropathies

Amyloid neuropathies
Amyloid neuropathies, familial
Amyloidosis, familial

Additional Relevant MeSH Terms

Proteostasis Deficiencies
Metabolic Diseases
Amyloidosis

Plan for Individual Participant Data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents, and helpful links

Studies a U.S. FDA-Regulated Drug Product

No

Studies a U.S. FDA-Regulated Device Product

No

Back to Results

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

ENROLLING

The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.

Trial at a Glance

Trial ID	**ALN-AGT01-007**
Condition	**Hypertension, High Cardiovascular Risk**
Drug/Treatment	**Placebo, Zilebesiran**
Does this trial use a placebo?	**Yes**
Trial Type	**Interventional**
Number of Participants	**390 participants**
Trial dates	**February 29, 2024 - December 19, 2025**

For more information: NCT06272487

Who can participate?

AGE

18+ Years

SEX

All

ACCEPTS HEALTHY VOLUNTEERS?

No

Where is the study taking place?

Search location

Houston - Houston, TX, USA
San Antonio - 2455 NE Interstate 410 Loop #150, San Antonio, TX 78217, USA
Shenandoah - Shenandoah, TX, USA
Pembroke Pines - Pembroke Pines, FL, USA
Sherman - Sherman, TX, USA
Splendora - Splendora, TX, USA
Stephenville - Stephenville, TX 76401, USA
Tomball - Tomball, TX, USA
Orlando - Orlando, FL, USA
Daytona Beach - Daytona Beach, FL, USA
Jacksonville - Jacksonville, FL, USA
Roseville - Roseville, MI 48066, USA
Ypsilanti - Ypsilanti, MI, USA



Alnylam Clinical Trial Information Line

1-877-ALNYLAM
clinicaltrials@alnylam.com

Inquire about a clinical trial

Contact Alnylam directly with any questions about our clinical trials.

CONTACT US ›

Alnylam®

Privacy policy Legal Notice Alnylam.com

Follow Us:

Back to Results

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

ENROLLING

The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.

Trial at a Glance

Trial ID	**ALN-BCAT-001**
Condition	**Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma**
Drug/Treatment	**ALN-BCAT, Pembrolizumab**
Does this trial use a placebo?	**No**
Trial Type	**Interventional**
Number of Participants	**158 participants**
Trial dates	**November 30, 2024 - October 31, 2027**

For more information: NCT06600321

Who can participate?

AGE

18+ Years

SEX

All

ACCEPTS HEALTHY VOLUNTEERS?

No

Where is the study taking place?

Search location

United States

Houston - Houston, TX, USA

San Antonio - 2455 NE Interstate 410 Loop #150, San Antonio, TX 78217, USA



Alnylam Clinical Trial Information Line

1-877-ALNYLAM
clinicaltrials@alnylam.com

Inquire about a clinical trial

Contact Alnylam directly with any questions about our clinical trials.

CONTACT US ›

Alnylam®

Privacy policy Legal Notice Alnylam.com

Follow Us: